Vol. 19 No. 1 (2018)

Published: 2018-01-30

Letter to the Editor

Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis

Diego Centonze, Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Luigi Giuliani, Pier Luigi Canonico
- HTML
- PDF

Original research

Healthcare Resources Use in Patients with Human Immunodeficiency Virus (HIV). Real-World Evidence From Six Italian Local Health Units

Valentina Perrone, Diego Sangiorgi, Stefano Buda, Margherita Andretta, Silvio Borrè, Chiara Cattaruzzi, Gina Gasperini, Fabio Lena, Alessia Pisterna, Luca Degli Esposti
- HTML
- PDF
Cost-Consequence Analysis of Three Different Diagnostic Strategies in the First- and Second-Line Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Giovanni Gancitano, Roberto Ravasio, Matteo Dionisi, Diego Cortinovis
- HTML
- PDF
Albutrepenonacog alfa (Idelvion®) for the treatment of Italian patients with hemophilia B: a budget impact model

Lorenzo Pradelli, Sara Villa, Giancarlo Castaman
- HTML
- PDF
Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation

Marco Bellone, Lorenzo Pradelli, Mario Bo
- HTML
- PDF

Focus On

Personalized medicine: biomarkers and companion diagnostics

Renato Bernardini, Giovanni Gancitano, Angela Balice, Rosaria Di Mauro, Giuseppina Cantarella, Matteo Dionisi
- HTML
- PDF

Acknowledgement to reviewers

Acknowledgement to Reviewers (January - December 2018)
- HTML
- PDF

Editorial Staff Disclosure

Editorial Staff Disclosure (2018)
- HTML
- PDF